CROI 2008 Coverage - 15th Conference on Retroviruses and Opportunistic Infections. HIV and Hepatitis.com Coverage

HIV and Hepatitis.com Coverage of the
15th Conference on Retroviruses and Opportunistic Infections (CROI 2008)
February 3 - 6, 2008, Boston, MA
The material posted on HIV and Hepatitis.com about CROI 2008 is not approved
by nor is it a part of CROI 2008.

LIbrary of Slides and Posters
HIV and AIDS Articles
HIV-HCV and HIV-HBV Coinfection Articles

ASSESSING BEST PRACTICES IN HIV/AIDS THERAPY

	HIV and AIDS Articles Top
	Boosted Darunavir (Prezista) Is Safe and Effective for Children with HIV
	Antiretroviral Regimen Should Be Modified Promptly after Virological Failure
	Do CCR5 Antagonists Boost CD4 Cell Counts More than Other Antiretroviral Drug Classes?
	More Questions than Answers from STEP HIV Vaccine Trials
	Second Virological Failure on Antiretroviral Therapy Is Now Less Common, but Still Hazardous
	Delaying HAART during Opportunistic Infection Treatment Leads to Disease Progression and Death
	Re-emergence of Drug-resistant Tuberculosis in HIV Positive People Is Due to Re-infection, Not Treatment Failure
	HAART Decreases Risk of Death Even in People with CD4 Counts above 350 Cells/mm3
	CD4 Cell Loss and Accelerated Atherosclerosis Occur Even in HIV Positive "Elite Controllers" with Undetectable Viral Load
	Once-daily Lopinavir/ritonavir (Kaletra) and Nevirapine (Viramune) Appear as Effective as Twice-daily
	Antiretroviral Therapy for Mothers and Infants Lowers Risk of HIV Transmission during Breast-feeding
	Vaginal Lactobacillus Lowers Genital Viral Load in Women with HIV
	Will Nanoparticle Technology Lead to Once-monthly HAART?
	Interruption of HAART Started during Acute or Recent HIV Infection: Final Results of ACTG 371
	Double Protease Inhibitor Therapy with Lopinavir/ritonavir (Kaletra) plus Atazanavir (Reyataz) in Treatment-naive Patients: LORAN Study
	AIDS-related Deaths in France Are More Frequent in Women than in Men since 2000
	Maraviroc (Selzentry): 48-week Treatment-experienced Data, Failure and Lipids in Treatment-naive patients, and Possible Use for Prevention
	Maraviroc (Selzentry): 48-week Treatment-experienced Data, Failure and Lipids in Treatment-naive patients, and Possible Use for Prevention
	Treating Genital Herpes with Acyclovir Fails to Lower Risk of HIV Infection
	Mechanisms for Elevated Risk of Cardiovascular Disease and Death in SMART and STACCATO Treatment Interruption Trials
	D:A:D NRTI Analysis Shows Abacavir (Ziagen) and ddI (Videx) Boost Cardiovascular Risk
	Raltegravir Shows Significant Reductions in HIV Viral Load and Increased CD4 cell Counts at 48 Weeks
	48-week Results on Efficacy and Safety of New Second Generation NNRTI Etravirine (Intelence)
	Therapeutic Drug Monitoring Demonstrates No Benefit in Randomized Controlled Trial
	Harms of Treatment Interruption Lessened, but Not Fully Reversed, after Restarting HAART: SMART Study
	CCR5 Antagonist Vicriviroc Shows Continued Benefits and Good Tolerability at 48 Weeks: VICTOR-E1 Trial
	New CCR5 Antagonist SCH32706 Demonstrates Anti-HIV Activity in First Clinical Trial
	Boosted Atazanavir (Reyataz) and Lopinavir/ritonavir (Kaletra) Have Similar Efficacy, but Different Side Effects: CASTLE Study
	Abacavir/3TC (Epzicom) Matches Tenofovir/Emtricitabine (Truvada) for Treatment-naive Patients: HEAT Study
	HIV-HCV / HIV-HBV Articles Top
	Hepatitis Flares in HIV-HBV Coinfected Patients Starting HAART May Be Due to Immune Restoration
	Treatment of Acute Hepatitis C in HIV Positive Individuals
	Do HIV-HCV Coinfected Patients Have Impaired CD4 Cell Recovery after Starting HAART
	Hepatitis B Coinfection Does Not Impact HIV Suppression or CD4 Cell Recovery on HAART
	Race, but Not HIV Status, Affects Early Hepatitis C Viral Kinetics
	Better Response to Hepatitis C Therapy in Coinfected Patients Taking Tenofovir (Viread), but Worse with AZT (Retrovir) or Abacavir (Ziagen)
	MELD Score Is the Best Predictor of Outcomes among HIV Positive Liver Transplant Recipients
	Rates and Risk Factors for Liver Fibrosis Progression in HIV-HCV Coinfected Individuals
	Vicriviroc Is Safe in HIV-HCV Coinfected Patients, but Does Not Show Activity against HCV
	Long-term Pegylated Interferon Maintenance Therapy Demonstrates No Benefit in HIV-HCV Coinfected Patients
	Re-emergence of HCV in British Gay Men Appears to Be Reinfection, Not Late Relapse
	Two Studies Look at Anti-HIV Activity of Entecavir (Baraclude)
	Sustained Response to Pegylated Interferon plus Ribavirin Reduces Liver Disease and Death in HIV Positive Patients
	Rapid Liver Fibrosis Progression in HIV Positive Men with Acute HCV Infection
	Fibrosis Status of HIV-HCV Coinfection Patients with Normal ALT Levels
	HIV Entry into Hepatic Stellate Cells Promotes Liver Fibrosis Progression
	Effect of HAART and Hepatitis B Vaccination on Epidemiology of HIV-HBV Coinfection
	Benefits of HAART and Outcomes among HIV-HBV Coinfected Men

BOSTON, MA